Dr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany;
Blood. 2013 Dec 19;122(26):4246-52; quiz 4292. doi: 10.1182/blood-2013-07-515825. Epub 2013 Oct 7.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of all Hodgkin lymphoma cases. The aim of this study was to evaluate the prognostic implication of histopathologic NLPHL variants. Biopsies of 423 NLPHL patients treated within 9 prospective clinical trials performed by the German Hodgkin Study Group were classified as tumor cell-rich cases (n = 10), typical NLPHL (n = 308), or histopathologic variants (n = 105). Histopathologic variants were characterized by the presence of lymphoma cells outside the B-cell nodules or B-cell depletion of the microenvironment. Compared with typical NLPHL, histopathologic variants were associated with advanced disease (29.5% vs 14.6%, P = .0012) and a higher relapse rate (18.1% vs 6.5% at 5 years, P = .0009). Variant histology represented an independent prognostic factor (odds ratio = 2.955) in a multivariate model of progression/relapse. A prognostic score, including the risk factors variant histopathologic growth pattern, low serum albumin, and male gender, was derived from this model and allowed the definition of 3 distinct risk groups. NLPHL patients presenting with histopathologic variants have a poorer outcome compared with those showing typical histology. The newly developed prognostic score combining histologic and clinical features allows allocating NLPHL patients to defined risk groups.
结节性淋巴细胞为主型霍奇金淋巴瘤 (NLPHL) 约占所有霍奇金淋巴瘤病例的 5%。本研究旨在评估组织病理学 NLPHL 变异体的预后意义。对德国霍奇金研究组进行的 9 项前瞻性临床试验中治疗的 423 例 NLPHL 患者的活检进行分类,分为肿瘤细胞丰富型病例 (n = 10)、典型 NLPHL (n = 308) 或组织病理学变异体 (n = 105)。组织病理学变异体的特征是淋巴瘤细胞存在于 B 细胞结节之外或微环境中的 B 细胞耗竭。与典型 NLPHL 相比,组织病理学变异体与晚期疾病相关 (29.5%比 14.6%,P =.0012) 和更高的复发率 (5 年时为 18.1%比 6.5%,P =.0009)。在进展/复发的多变量模型中,变异组织学代表独立的预后因素 (比值比 = 2.955)。该模型得出了一个预后评分,包括变异组织病理学生长模式、低血清白蛋白和男性等风险因素,可将 NLPHL 患者定义为 3 个不同的风险组。与表现出典型组织学的患者相比,表现出组织病理学变异的 NLPHL 患者预后更差。结合组织学和临床特征的新开发的预后评分可将 NLPHL 患者分配到特定的风险组。